| Revealing the impact of structural variants in multiple myeloma EH Rustad, VD Yellapantula, D Glodzik, KH Maclachlan, B Diamond, ... Blood cancer discovery 1 (3), 258-273, 2020 | 92 | 2020 |
| COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 81 | 2020 |
| Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities B Oben, G Froyen, KH Maclachlan, D Leongamornlert, F Abascal, ... Nature communications 12 (1), 1861, 2021 | 77 | 2021 |
| Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the … O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, ... JAMA oncology 7 (6), 862-868, 2021 | 71 | 2021 |
| Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial B Diamond, N Korde, AM Lesokhin, EL Smith, U Shah, S Mailankody, ... The Lancet Haematology 8 (6), e422-e432, 2021 | 56 | 2021 |
| Accelerated single cell seeding in relapsed multiple myeloma HJ Landau, V Yellapantula, BT Diamond, EH Rustad, KH Maclachlan, ... Nature communications 11 (1), 3617, 2020 | 44 | 2020 |
| Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma F Maura, EH Rustad, V Yellapantula, M Łuksza, D Hoyos, KH Maclachlan, ... Leukemia 34 (5), 1476-1480, 2020 | 42 | 2020 |
| The mutagenic impact of melphalan in multiple myeloma F Maura, N Weinhold, B Diamond, D Kazandjian, L Rasche, G Morgan, ... Leukemia 35 (8), 2145-2150, 2021 | 39 | 2021 |
| Second malignancies in multiple myeloma; emerging patterns and future directions K Maclachlan, B Diamond, F Maura, J Hillengass, I Turesson, ... Best Practice & Research Clinical Haematology 33 (1), 101144, 2020 | 35 | 2020 |
| Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma KH Maclachlan, EH Rustad, A Derkach, B Zheng-Lin, V Yellapantula, ... Nature communications 12 (1), 5172, 2021 | 32 | 2021 |
| CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) F Maura, A Dodero, C Carniti, N Bolli, M Magni, V Monti, A Cabras, ... Haematologica 106 (11), 2918, 2021 | 24 | 2021 |
| Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity BT Diamond, E Rustad, K Maclachlan, K Thoren, C Ho, M Roshal, ... Blood reviews 46, 100732, 2021 | 23 | 2021 |
| Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high … C Ho, M Syed, M Roshal, K Petrova-Drus, C Moung, J Yao, AE Quesada, ... The Journal of Molecular Diagnostics 23 (2), 181-199, 2021 | 21 | 2021 |
| Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures B Diamond, B Ziccheddu, K Maclachlan, J Taylor, E Boyle, JA Ossa, ... Blood, The Journal of the American Society of Hematology 141 (19), 2359-2371, 2023 | 19 | 2023 |
| Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets UA Shah, KH Maclachlan, A Derkach, M Salcedo, K Barnett, J Caple, ... Clinical Cancer Research 28 (23), 5149-5155, 2022 | 19 | 2022 |
| Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use KH Maclachlan, N Came, B Diamond, M Roshal, C Ho, K Thoren, ... Pathology 53 (3), 385-399, 2021 | 13 | 2021 |
| Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma G Jonsdottir, M Björkholm, I Turesson, M Hultcrantz, B Diamond, A Porwit, ... European journal of haematology 107 (2), 275-282, 2021 | 12 | 2021 |
| Positive selection as the unifying force for clonal evolution in multiple myeloma B Diamond, V Yellapantula, EH Rustad, KH Maclachlan, M Mayerhoefer, ... Leukemia 35 (5), 1511-1515, 2021 | 12 | 2021 |
| Mantle cell lymphoma: current and emerging treatment strategies and unanswered questions B Diamond, A Kumar Hematology/Oncology Clinics 33 (4), 613-626, 2019 | 11 | 2019 |
| Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length EM Boyle, L Williams, P Blaney, C Ashby, M Bauer, BA Walker, ... Leukemia 36 (1), 221-224, 2022 | 10 | 2022 |
